JP2017503820A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017503820A5 JP2017503820A5 JP2016547570A JP2016547570A JP2017503820A5 JP 2017503820 A5 JP2017503820 A5 JP 2017503820A5 JP 2016547570 A JP2016547570 A JP 2016547570A JP 2016547570 A JP2016547570 A JP 2016547570A JP 2017503820 A5 JP2017503820 A5 JP 2017503820A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- pharmaceutical composition
- administered
- composition according
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461929716P | 2014-01-21 | 2014-01-21 | |
| US61/929,716 | 2014-01-21 | ||
| US201461944361P | 2014-02-25 | 2014-02-25 | |
| US61/944,361 | 2014-02-25 | ||
| US201462021397P | 2014-07-07 | 2014-07-07 | |
| US62/021,397 | 2014-07-07 | ||
| PCT/US2015/012212 WO2015112578A1 (en) | 2014-01-21 | 2015-01-21 | Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019166361A Division JP7164502B2 (ja) | 2014-01-21 | 2019-09-12 | 遺伝性血管浮腫の治療における血漿カリクレイン結合タンパク質およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017503820A JP2017503820A (ja) | 2017-02-02 |
| JP2017503820A5 true JP2017503820A5 (cg-RX-API-DMAC7.html) | 2018-03-01 |
| JP6845012B2 JP6845012B2 (ja) | 2021-03-17 |
Family
ID=53681890
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016547570A Active JP6845012B2 (ja) | 2014-01-21 | 2015-01-21 | 遺伝性血管浮腫の治療における血漿カリクレイン結合タンパク質およびその使用 |
| JP2019166361A Active JP7164502B2 (ja) | 2014-01-21 | 2019-09-12 | 遺伝性血管浮腫の治療における血漿カリクレイン結合タンパク質およびその使用 |
| JP2022168140A Pending JP2023015087A (ja) | 2014-01-21 | 2022-10-20 | 遺伝性血管浮腫の治療における血漿カリクレイン結合タンパク質およびその使用 |
| JP2024151126A Pending JP2024170495A (ja) | 2014-01-21 | 2024-09-03 | 遺伝性血管浮腫の治療における血漿カリクレイン結合タンパク質およびその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019166361A Active JP7164502B2 (ja) | 2014-01-21 | 2019-09-12 | 遺伝性血管浮腫の治療における血漿カリクレイン結合タンパク質およびその使用 |
| JP2022168140A Pending JP2023015087A (ja) | 2014-01-21 | 2022-10-20 | 遺伝性血管浮腫の治療における血漿カリクレイン結合タンパク質およびその使用 |
| JP2024151126A Pending JP2024170495A (ja) | 2014-01-21 | 2024-09-03 | 遺伝性血管浮腫の治療における血漿カリクレイン結合タンパク質およびその使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11084884B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3096798B1 (cg-RX-API-DMAC7.html) |
| JP (4) | JP6845012B2 (cg-RX-API-DMAC7.html) |
| KR (3) | KR102424183B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN106132442B (cg-RX-API-DMAC7.html) |
| AU (3) | AU2015209481C1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112016016916B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2937329C (cg-RX-API-DMAC7.html) |
| DK (1) | DK3096798T3 (cg-RX-API-DMAC7.html) |
| EA (1) | EA038532B1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2856076T3 (cg-RX-API-DMAC7.html) |
| IL (3) | IL246864B (cg-RX-API-DMAC7.html) |
| MX (2) | MX387753B (cg-RX-API-DMAC7.html) |
| NZ (2) | NZ761006A (cg-RX-API-DMAC7.html) |
| PL (1) | PL3096798T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT3096798T (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015112578A1 (cg-RX-API-DMAC7.html) |
| ZA (2) | ZA201605342B (cg-RX-API-DMAC7.html) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2905545T3 (es) | 2010-01-06 | 2022-04-11 | Takeda Pharmaceuticals Co | Proteínas de unión a calicreína plasmática |
| CN105713092B (zh) * | 2011-01-06 | 2019-09-10 | 戴埃克斯有限公司 | 血浆前激肽释放酶结合蛋白 |
| SMT201800563T1 (it) | 2013-01-20 | 2018-11-09 | Dyax Corp | Valutazione e trattamento di disturbi mediati da bradichinina |
| JP2016513682A (ja) | 2013-03-15 | 2016-05-16 | ダイアックス コーポレーション | 抗血漿カリクレイン抗体 |
| EP3060582B1 (en) | 2013-10-21 | 2020-09-23 | Dyax Corp. | Assays for determining plasma kallikrein system biomarkers |
| US10101344B2 (en) | 2013-10-21 | 2018-10-16 | Dyax Corp. | Diagnosis and treatment of autoimmune diseases |
| PT3096798T (pt) | 2014-01-21 | 2021-02-25 | Dyax Corp | Proteínas de ligação à calicreína plasmática e seus usos no tratamento de angioedema hereditário |
| US10428158B2 (en) | 2014-03-27 | 2019-10-01 | Dyax Corp. | Compositions and methods for treatment of diabetic macular edema |
| HK1250995A1 (zh) * | 2015-03-30 | 2019-01-18 | Takeda Pharmaceutical Company Limited | 血浆激肽释放酶抑制剂及预防遗传性血管神经性水肿发作的用途 |
| WO2017035263A1 (en) * | 2015-08-24 | 2017-03-02 | Biocryst Pharmaceuticals, Inc. | Compositions comprising a plasma kallikrein inhibitor |
| DK3365685T3 (da) | 2015-10-19 | 2021-03-01 | Dyax Corp | Immunoassay til påvisning af spaltet højmolekylært kininogen |
| BR112018011622A2 (pt) * | 2015-12-11 | 2018-11-27 | Dyax Corp | método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae |
| WO2018053260A1 (en) | 2016-09-16 | 2018-03-22 | Dyax Corp. | Rna biomarkers for hereditary angioedema |
| CN109716138B (zh) * | 2016-09-16 | 2023-10-03 | 武田药品工业株式会社 | 用于接触活化系统相关的疾病的蛋白生物标记 |
| EP4509527A3 (en) * | 2017-10-18 | 2025-04-30 | REGENXBIO Inc. | Post-translationally modified fully human antibody therapeutic agents |
| AU2018374219C1 (en) | 2017-12-01 | 2023-05-11 | Suzhou Ribo Life Science Co., Ltd. | Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method therefor and use thereof |
| CN118291457A (zh) | 2017-12-01 | 2024-07-05 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| EP4455285A3 (en) | 2017-12-01 | 2025-02-26 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof |
| EP3718572B1 (en) | 2017-12-01 | 2024-07-31 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing nucleic acid, preparation method and use |
| CN110997917B (zh) | 2017-12-01 | 2024-04-09 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| KR102617947B1 (ko) | 2017-12-29 | 2023-12-27 | 쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 | 접합체와 제조 및 그 용도 |
| WO2020038377A1 (zh) | 2018-08-21 | 2020-02-27 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的药物组合物和缀合物及其用途 |
| CN111655297A (zh) | 2018-09-30 | 2020-09-11 | 苏州瑞博生物技术有限公司 | 一种siRNA缀合物及其制备方法和用途 |
| EP3903830A4 (en) | 2018-12-28 | 2023-04-26 | Suzhou Ribo Life Science Co., Ltd. | NUCLEIC ACID, COMPOSITION AND CONJUGATE WITH NUCLEIC ACID, PROCESS FOR THEIR PREPARATION AND ITS USE |
| US12163956B2 (en) | 2019-02-21 | 2024-12-10 | Takeda Pharmaceutical Company Limited | Lateral flow immunoassay for measuring functional C1-esterase inhibitor (C1-INH) in plasma samples |
| US20200317815A1 (en) * | 2019-03-14 | 2020-10-08 | Dyax Corp. | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
| CN113227376B (zh) | 2019-05-22 | 2024-04-09 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| EP3992290A4 (en) * | 2019-05-24 | 2023-11-15 | Suzhou Ribo Life Science Co., Ltd. | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND CONJUGATE, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF |
| JP2023521667A (ja) * | 2020-04-04 | 2023-05-25 | 武田薬品工業株式会社 | 血漿カリクレイン阻害剤及び急性呼吸窮迫症候群を処置するためのその使用 |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| US5444156A (en) | 1985-07-12 | 1995-08-22 | Temple University-Of The Commonwealth System Of Higher Education | Monoclonal antibodies to human plasma prekallikrein |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| EP0296171A4 (en) | 1986-03-03 | 1989-11-07 | Brigham & Womens Hospital | ASSESSMENT PROCEDURE FOR NEPHROTOXICITY. |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US5045452A (en) | 1988-09-02 | 1991-09-03 | Brigham And Women's Hospital | Method for evaluating nephrotoxicity |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
| CA2180950C (en) | 1994-01-11 | 2005-03-29 | William Markland | Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| DE19632772A1 (de) | 1996-08-14 | 1998-02-19 | Basf Ag | Neue Benzamidine |
| US5840871A (en) | 1997-01-29 | 1998-11-24 | Incyte Pharmaceuticals, Inc. | Prostate-associated kallikrein |
| US6913900B2 (en) | 2001-08-29 | 2005-07-05 | Nippon Zoki Pharmaceutical Co., Ltd. | Plasma prekallikrein activation and kallikrein production assay |
| US20030138417A1 (en) | 2001-11-08 | 2003-07-24 | Kaisheva Elizabet A. | Stable liquid pharmaceutical formulation of IgG antibodies |
| EP2298278B1 (en) | 2002-06-07 | 2015-11-11 | Dyax Corp. | Prevention and reduction of blood loss and inflammatory response |
| US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| JP4653660B2 (ja) | 2003-09-04 | 2011-03-16 | 独立行政法人理化学研究所 | ＴＧＦ−β活性化制御領域の切断面を認識する抗体 |
| WO2005075665A2 (en) | 2004-02-03 | 2005-08-18 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with plasma kallikrein (klkb1) |
| JP2008515774A (ja) | 2004-08-03 | 2008-05-15 | ダイアックス コーポレイション | ｈＫ１結合タンパク質 |
| US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
| WO2007104541A2 (en) | 2006-03-16 | 2007-09-20 | Dyax Corp. | Compositions and methods using serine protease inhibiting peptides for treating ophthalmic disorders |
| EP2051707B1 (en) | 2006-07-31 | 2013-07-17 | Activesite Pharmaceuticals, Inc. | Inhibitors of plasma kallikrein |
| CN101495468A (zh) * | 2006-07-31 | 2009-07-29 | 艾克提弗赛特制药股份有限公司 | 血浆激肽释放酶抑制剂 |
| KR100846354B1 (ko) | 2007-03-21 | 2008-07-15 | (주) 프로탄바이오 | 혈청 당단백질부터 분리한 폐암 진단용 마커 |
| JP2010533657A (ja) * | 2007-07-20 | 2010-10-28 | ジェネシス ベンチャー インコーポレーテッド | アミロイドタンパク質に関係する疾患を治療するための組織カリクレイン |
| AU2008288772A1 (en) | 2007-08-23 | 2009-02-26 | Genzyme Corporation | Treatment with kallikrein inhibitors |
| AU2009266856A1 (en) | 2008-07-02 | 2010-01-07 | Emergent Product Development Seattle, Llc | IL6 immunotherapeutics |
| AU2010203712A1 (en) | 2009-01-06 | 2010-07-15 | Dyax Corp. | Treatment of mucositis with kallikrein inhibitors |
| CN101928346B (zh) | 2009-07-31 | 2013-01-16 | 华中科技大学同济医学院附属同济医院 | 一种抗人组织激肽释放酶单克隆抗体及其制备 |
| ES2905545T3 (es) | 2010-01-06 | 2022-04-11 | Takeda Pharmaceuticals Co | Proteínas de unión a calicreína plasmática |
| CN105713092B (zh) | 2011-01-06 | 2019-09-10 | 戴埃克斯有限公司 | 血浆前激肽释放酶结合蛋白 |
| US8691861B2 (en) | 2011-04-13 | 2014-04-08 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
| ES2646717T3 (es) | 2011-05-02 | 2017-12-15 | Millennium Pharmaceuticals, Inc. | Formulación para anticuerpo anti- 4 7 |
| MX370199B (es) | 2012-02-16 | 2019-12-05 | Santarus Inc | Composiciones farmaceuticas de anticuerpo anti-antigeno muy tardio (cd49a). |
| US9216219B2 (en) | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
| HUE044285T2 (hu) | 2013-01-20 | 2019-10-28 | Dyax Corp | PKal-mediálta rendellenességek értékelése, vizsgálata és kezelése |
| SMT201800563T1 (it) | 2013-01-20 | 2018-11-09 | Dyax Corp | Valutazione e trattamento di disturbi mediati da bradichinina |
| JP2016513682A (ja) | 2013-03-15 | 2016-05-16 | ダイアックス コーポレーション | 抗血漿カリクレイン抗体 |
| KR20140119396A (ko) | 2013-03-29 | 2014-10-10 | 삼성전자주식회사 | 단백질 약물의 액상 제형 |
| EP3060582B1 (en) | 2013-10-21 | 2020-09-23 | Dyax Corp. | Assays for determining plasma kallikrein system biomarkers |
| PT3096798T (pt) | 2014-01-21 | 2021-02-25 | Dyax Corp | Proteínas de ligação à calicreína plasmática e seus usos no tratamento de angioedema hereditário |
| US10428158B2 (en) | 2014-03-27 | 2019-10-01 | Dyax Corp. | Compositions and methods for treatment of diabetic macular edema |
| HK1250995A1 (zh) | 2015-03-30 | 2019-01-18 | Takeda Pharmaceutical Company Limited | 血浆激肽释放酶抑制剂及预防遗传性血管神经性水肿发作的用途 |
| BR112018011622A2 (pt) | 2015-12-11 | 2018-11-27 | Dyax Corp | método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae |
| CN117169508A (zh) * | 2016-09-16 | 2023-12-05 | 武田药品工业株式会社 | 用于与接触活化系统相关的疾病的代谢产物生物标记 |
| WO2019048960A1 (en) | 2017-09-05 | 2019-03-14 | Bat Call D. Adler Ltd. | ELECTRONIC STHETHOSCOPE WITH IMPROVED FEATURES |
| WO2020047352A1 (en) | 2018-08-30 | 2020-03-05 | Dyax Corp. | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
| US20200317815A1 (en) | 2019-03-14 | 2020-10-08 | Dyax Corp. | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
| WO2021146160A1 (en) | 2020-01-13 | 2021-07-22 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack |
-
2015
- 2015-01-21 PT PT157407743T patent/PT3096798T/pt unknown
- 2015-01-21 CA CA2937329A patent/CA2937329C/en active Active
- 2015-01-21 EA EA201691470A patent/EA038532B1/ru unknown
- 2015-01-21 WO PCT/US2015/012212 patent/WO2015112578A1/en not_active Ceased
- 2015-01-21 EP EP15740774.3A patent/EP3096798B1/en active Active
- 2015-01-21 EP EP20209536.0A patent/EP3848057B1/en active Active
- 2015-01-21 CN CN201580010172.XA patent/CN106132442B/zh active Active
- 2015-01-21 AU AU2015209481A patent/AU2015209481C1/en active Active
- 2015-01-21 CN CN202310760869.5A patent/CN116585468A/zh active Pending
- 2015-01-21 KR KR1020167022785A patent/KR102424183B1/ko active Active
- 2015-01-21 NZ NZ761006A patent/NZ761006A/en unknown
- 2015-01-21 JP JP2016547570A patent/JP6845012B2/ja active Active
- 2015-01-21 KR KR1020227025028A patent/KR20220107077A/ko not_active Ceased
- 2015-01-21 NZ NZ723369A patent/NZ723369A/en unknown
- 2015-01-21 BR BR112016016916-6A patent/BR112016016916B1/pt active IP Right Grant
- 2015-01-21 PL PL15740774T patent/PL3096798T3/pl unknown
- 2015-01-21 US US15/113,297 patent/US11084884B2/en active Active
- 2015-01-21 DK DK15740774.3T patent/DK3096798T3/da active
- 2015-01-21 ES ES15740774T patent/ES2856076T3/es active Active
- 2015-01-21 KR KR1020247010766A patent/KR20240049627A/ko active Pending
- 2015-01-21 MX MX2016009428A patent/MX387753B/es unknown
-
2016
- 2016-07-20 MX MX2021013665A patent/MX2021013665A/es unknown
- 2016-07-20 IL IL246864A patent/IL246864B/en active IP Right Grant
- 2016-08-02 ZA ZA201605342A patent/ZA201605342B/en unknown
-
2018
- 2018-12-12 IL IL263669A patent/IL263669B/en active IP Right Grant
-
2019
- 2019-09-12 JP JP2019166361A patent/JP7164502B2/ja active Active
-
2020
- 2020-07-28 ZA ZA2020/04653A patent/ZA202004653B/en unknown
- 2020-09-02 US US17/010,354 patent/US12384854B2/en active Active
- 2020-09-28 AU AU2020244370A patent/AU2020244370B2/en active Active
- 2020-10-14 IL IL278062A patent/IL278062B/en unknown
-
2022
- 2022-10-20 JP JP2022168140A patent/JP2023015087A/ja active Pending
-
2024
- 2024-05-23 AU AU2024203436A patent/AU2024203436A1/en active Pending
- 2024-09-03 JP JP2024151126A patent/JP2024170495A/ja active Pending